Market Trends of Global Axial Spondyloarthritis (axSpA) Industry
This section covers the major market trends shaping the Axial Spondyloarthritis (axSpA) Market according to our research experts:
The Non-steroidal Anti Inflammatory Drug Class Segment is Expected to Hold a Major Market Share in the Studied Period
The nonsteroidal anti-inflammatory drug class Segment occupies a major share of the market over the forecast period. Nonsteroidal anti-inflammatory drugs (NSAIDs) are highly effective and most commonly used in the treatment of axial spondyloarthritis.
Treatment for axSpA usually starts with nonsteroidal anti-inflammatory drugs (NSAIDs). Nonsteroidal anti-inflammatory drugs (NSAIDs) are highly effective against the major symptoms of axSpA (pain and stiffness) and may have disease-modifying properties, including retarding the progression of structural damage in the spine. Therefore, NSAIDs, unless contraindicated, are the treatment of choice for the majority of patients with axSpA. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen (Naprosyn) and indomethacin (Indocin and Tivorbex), are the medications preferred by doctors.
Furthermore, new product launches are likely to fuel the treatment market, as they are used as the first line of treatment. For instance, in July 2022, RINVOQ (upadacitinib) was approved by European Commission as an oral treatment for adults with active non-radiographic axial spondyloarthritis.
Thus, the segment is anticipated to witness significant growth over the forecast period due to the abovementioned factors.
North America Holds a Significant Share and is Expected to Follow the Same Trend Over the Forecast Period
North America is expected to hold a significant market share in the global Axial spondyloarthritis market due to a rise in awareness, increasing prevalence in this region, and improved diagnosis. The United States is the most affected country across the world, as there are higher numbers of patients suffering from Axial spondyloarthritis and higher in the North America region as the patient population is increasing compared to other countries.
North America is expected to hold a significant market share in the global Axial spondyloarthritis market due to a rise in awareness, increasing prevalence in this region, and improved diagnosis. As per a study published in The American Journal of Managed Care (AJMC) in January 2020 titled ''Understanding Axial Spondyloarthritis: A Primer for Managed Care, approximately 1.5 million Americans are affected by axial spondyloarthritis, with estimates of axial spondyloarthritis prevalence ranging from 0.9% to 1.4%. Typically, axial spondyloarthritis affects the younger spondyloarthritis patient population, with an average age of symptom onset of 28 years. Additionally, as per the study published in July 2021 titled 'Investigating Diagnosis, Treatment, and Burden of Disease in Patients with Ankylosing Spondylitis in Central Eastern Europe and the United States: A Real-World Study, the prevalence of ankylosing spondylitis ranged from 9 to 30 per 10,000 persons, which is lower than previous estimates. The progression of patients with non-radiographic axial spondyloarthritis to ankylosing spondylitis is slow, with forecasts of 5.1% in 5 years and 19% in 10 years.
Moreover, high expenditure on healthcare, especially in the United States and Canada, and increased awareness about the disease are fueling the growth of the overall regional market to a large extent.
